A Phase 2 Randomized, Double-blind, Placebo-controlled Safety and Efficacy Trial of Deupirfenidone (LYT-100) in Post-acute COVID-19 Respiratory Disease
Lay Description
Category
- COVID-19
- Infections / Infectious Diseases
- Lungs, Breathing and Bronchial
- IRB Number
- 20200938HU
- NCT Number
- ct.gov registration not required
- Open to Enrollment
- Yes
Eligibility
- Eligible Ages
- Eligible Genders
- Accepts Healthy Volunteers
Inclusion Criteria
Exclusion Criteria
Study Design
Arm Groups
Study Contact
Regulatory Point of Contact
Irma Scholler
+1 (210) 450-3150
scholler@uthscsa.edu
Regulatory Point of Contact
Robin Tragus
(210) 567-5262
tragus@uthscsa.edu
Principal Investigator
Thomas Patterson